ImmunityBio Shares Are Trading Higher After Piper Sandler Maintained a Neutral Rating on the Stock and Raised Its Price Target From $5 to $6
在派珀·桑德勒维持对该股的中性评级并将其目标股价从5美元上调至6美元之后,ImmunityBio股价走高
ImmunityBio Shares Are Trading Higher After Piper Sandler Maintained a Neutral Rating on the Stock and Raised Its Price Target From $5 to $6
在派珀·桑德勒维持对该股的中性评级并将其目标股价从5美元上调至6美元之后,ImmunityBio股价走高
使用浏览器的分享功能,分享给你的好友吧